In what was a busy deal-making day for Maruho, the company announced licensing agreements with two fellow Japanese drugmakers, Astellas Pharma and Chugai. 29 September 2016
The US Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for dupilumab, a treatment for adults with inadequately controlled moderate-to-severe atopic dermatitis (AD), a serious, chronic inflammatory skin disease. 26 September 2016
Taltz (ixekizumab), a monoclonal antibody (MOA) from US pharma major Eli Lilly, and Swiss pharma giant Novartis’ Cosentyx (secukinumab), will make gains in the psoriasis market at the cost of sales of TNF-inhibitors, predicts a report based on a survey of 99 US dermatologists. 20 September 2016
Ireland-incorporated Allergan has strengthened its dermatology pipeline with the $639 million purchase of US biotech Vitae Pharmaceuticals. 14 September 2016
Dermira has entered into an exclusive option and license agreement with Takeda Pharmaceutical for worldwide rights for up to three early-stage, small-molecule programs as potential topical treatments for dermatologic diseases. 13 September 2016
Almirall has announced positive data from a Phase III randomized, double-blind, vehicle-controlled study evaluating the efficacy and safety of its already marketed Actikerall (5-fluorouracil (5-FU) 0.5%/salicylic acid 10%) when applied once daily as field-directed treatment to actinic keratosis (AK) lesions. 7 September 2016
Canadian topical drug developer Crescita Therapeutics said today that it has acquired INTEGA Skin Sciences, a Montreal-based dermatology company which develops, manufactures, sells and markets science-based quality skin care products. 1 September 2016
Australia-headquartered Mayne Pharma says it has acquired a portfolio of on-market dermatology foam assets from UK pharma major GlaxoSmithKline for $50.1 million. 19 August 2016
Mallinckrodt has entered into a merger agreement with Stratatech Corp, a privately-held Wisconsin-based regenerative medicine company focused on the development of unique, proprietary skin substitute products. 11 August 2016
Canada-based drugmaker Valeant Pharmaceuticals' share price soared by more than a quarter on Tuesday – despite missing analyst predictions in its quarterly results. 10 August 2016
Canada’s Cardiome Pharma says that Xydalba (dalbavancin) has been approved by the European Medicines Agency for administration as a single, 30 minute, 1500mg infusion (three 500mg vials). 10 August 2016
The drug cost-effectiveness watchdog for England and Wales, the National Institute for Health and Care Excellence (NICE), has published draft guidance recommending apremilast, a drug marketed by US biotech firm Celgene as Otezla, for psoriasis patients. 3 August 2016
India's Sun Pharmaceutical and Spain’s Almirall have announced a licensing agreement on the development and commercialization of tildrakizumab for psoriasis in Europe. 28 July 2016
At around six weeks after launch of Eli Lilly's interleukin (IL)-17 inhibitor Taltz (ixekizumab), one-third of surveyed dermatologists (n=99) report trialling the latest biologic, according to RealTime Dynamix: Psoriasis. 28 July 2016
Spain's leading drugmaker Almirall has reported that its total revenue in the first half of 2016 was 428.1 million euros ($470.8 million), which is 5% higher than in the same period of 2015. 26 July 2016
Spain’s leading drugmaker Almirall has entered through USA-based Aqua into a global licensing agreement with Patagonia Pharmaceuticals, a specialty US company developing innovative prescription therapies for rare dermatological diseases. 23 July 2016
Chugai Pharmaceuticals and Switzerland’s Galderma have entered into a global license agreement for nemolizumab (CIM331) the anti-interleukin (IL)-31 receptor A humanized monoclonal antibody created by Chugai. 21 July 2016
Shares in Canadian drugmaker Valeant took an upturn on Wednesday with the news that a US Food and Drug Administration advisory committee had voted unanimously in favor of approving Siliq (brodalumab) for adult patients with moderate-to-severe plaque psoriasis. 20 July 2016
Briefing documents prepared for a US Food and Drug Administration advisory committee have raised concerns on a potential suicide risk involving Siliq (brodalumab), a psoriasis treatment being developed by Canada’s Valeant Pharmaceuticals. 18 July 2016
The atopic dermatitis (AD) market is on track to reach $16.7 billion across mature markets by 2030, according to data and analytics company GlobalData. 19 September 2024
Danish clinical-stage techbio firm Evaxion Biotech, which is developing AI-Immunology powered vaccines, announced new clinical Phase II data for its lead compound EVX-01. 9 September 2024
Danish dermatology specialist LEO Pharma has presented a range of new population-level and physician-reported data on the prevalence, severity and treatment of moderate to severe chronic hand eczema (CHE). 5 September 2024
Biocon Biologics has signed a settlement and license agreement with Johnson & Johnson that clears the way to commercialize its Bmab 1200, a proposed biosimilar to Stelara (ustekinumab), in Europe, the UK, Canada, and Japan. 3 September 2024
South Korea’s Celltrion yesterday announced the European Commission (EC) approval for the use of SteQeyma (CT-P43), an ustekinumab biosimilar referencing Stelara, for the treatment of multiple chronic inflammatory diseases. 27 August 2024
Danish dermatology specialist LEO Pharma’s Timber Pharmaceuticals subsidiary has announced disappointing results for the randomized, double-blind 12-week period of the ASCEND trial. 23 August 2024
San Diego, USA-based biotech AnaptysBio (Nasdaq: ANAB) yesterday announced the pricing of an underwritten offering of 2,750,498 shares of its common stock at a price of $36.50 per share, representing a premium of approximately 10% to Anaptys’ closing price on August 13, 2024. 15 August 2024
Shares of American dermatology company Verrica Pharmaceuticals had a roller-coaster start to the day after announcing what it called positive trial results. 14 August 2024
The US Food and Drug Administration (FDA) has approved Galderma’s Nemluvio (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. 14 August 2024
The US subsidiary of South Korea’s Celltrion announced its US Food and Drug Administration (FDA)-approved biosimilar adalimumab-aaty has been added to the Costco member prescription program. 14 August 2024
Crown Laboratories, a privately held skincare company, and Nashville, USA-based Revance Therapeutics have entered into an agreement whereby the companies seek to merge the two complementary organizations. 13 August 2024
BioNTech released positive top-line data from the ongoing Phase II clinical trial in patients with unresectable stage III or IV melanoma whose disease had progressed following anti-PD-(L)1-containing treatment. 30 July 2024
California’s Arcutis Biotherapeutics, a biopharma developing innovations in immuno-dermatology, has announced the US commercial launch of Zoryve (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children down to age six years. 30 July 2024
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended seven novel medicines for approval at its July 2024 meeting. 26 July 2024
“Circle of Goodness,” one of Russia’s largest public funds, specializing on procurements of drugs for children with rare diseases, will begin procurements of the US drug Vyjuvek (beremagen heperpavec), which is designed for patients with epidermolysis bullosa (butterfly syndrome), reports The Pharma Letter’s local correspondent. 25 July 2024